LFMD LIFEMD INC

LifeMD to Report Second Quarter 2023 Financial Results on August 9

LifeMD to Report Second Quarter 2023 Financial Results on August 9

NEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended June 30, 2023 after the close of the U.S. financial markets on August 9, 2023 and will host a conference call beginning at 4:30 p.m. Eastern time.

Conference Call & Webcast Details

Date:Wednesday, August 9th
Time:4:30 p.m. Eastern Time
Toll-Free Dial-In:1-877-704-4453
International Dial-In:1-201-389-0920
Conference ID:13739131
Live & Archived Webcast:



About LifeMD™

LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to .

Media Contact

Investor Contact

Marc Benathen, CFO



EN
26/07/2023

Underlying

LFMDLIFEMD INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIFEMD INC

 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD to Participate in Two Investor Conferences During March

LifeMD to Participate in Two Investor Conferences During March NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March: Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside chat on Wednesday, March 18th at 9:00 a.m. ...

March 3, 2026 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9 NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archiv...

February 23, 2026 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD Announces Closing of $50 Million Revolving Credit Facility with...

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A. NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was dra...

January 6, 2026 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealt...

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is Novo Nordisk’s Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end teleh...

January 5, 2026 1 EN
 PRESS RELEASE
Free
LFMD LIFEMD INC

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Pr...

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026. About LifeMD, Inc.LifeMD® is a leading provide...

December 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch